ArticleJournal of translational medicine2026
Structural dynamics of microtubules in glioma: impact on macrophage M2 polarization and tumor cell heterogeneity.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundGlioma is the most common malignant brain tumor, characterized by high heterogeneity and poor prognosis. Microtubule dynamics regulate tumor progression and immune escape; however, the prognostic significance of microtubule-associated genes in glioma and their immunological significance still lack systematic investigation.
methodsWe integrated transcriptomic and clinical data from TCGA and CGGA cohorts to identify microtubule-associated genes with prognostic significance. A risk score (RS) model was established using Cox regression and validated in independent cohorts. Spatial transcriptomics and single-cell RNA sequencing were applied to characterize the expression patterns of candidate genes across glioma microregions and immune cell populations. Functional enrichment analysis, immune infiltration assessment, and drug sensitivity profiling were performed to explore the biological mechanisms and clinical implications of the RS model.
resultsWe identified 18 microtubule-associated genes that are significantly associated with glioma prognosis and constructed a three-gene RS model (PAFAH1B1, SNAPIN, and MAD1L1), which robustly predicts overall survival. Tumors with high-RS exhibited increased infiltration of M2 macrophages, enhanced immunosuppressive signaling, and reduced sensitivity to alkylating agents. Spatial and single-cell analyses confirmed that core RS genes are enriched at the tumor-immune interface and shaped macrophage polarization dynamics.
conclusionOur findings highlight microtubule-associated genes as key regulators of the glioma immune microenvironment. The RS model serves as a clinically applicable biomarker for prognostication and therapeutic stratification, with potential implications for optimizing immunotherapy and chemotherapy strategies in glioma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.